List of Bioinformatics Companies in Pennsylvania - 14

Develops a software solution, NICUtrition™, to improve thecare of preterm infants by providing quantitative data about gut health, allowing for personalized care and nutrition to optimize growth and outcomes.

Avammune Therapeutics is a drug discovery company focused on the development of novel immunotherapeutics to address high unmet medical needs. Our research is driven by the science that have a potential to create a significant difference on the disease platform. Our expertise lies on developing small molecule drugs that can be administered systemically and can potentially overcome the issues faced by the currently available therapeutics for cancer and immunological disorders. We work with experts in disease biology to achieve this goal which aims at improving the lives of patients significantly. Our research efforts has led to successful completion of projects in the immunoncology space.

Consegna Pharma Inc. is a specialty pharmaceutical company with a mission to create best-in-class long-acting medications.

Every Cure is a nonprofit initiative on a mission to unlock the full potential of existing medicines to treat every disease and every patient they possibly can.

Novasenta discovers novel therapeutic targets to develop innovative and effective treatments with the goal of transforming the lives of patients with cancer

Ocean Genomics works with biopharma, academic researchers and advocacy to empower discovery and development. We provide our advanced computing platforms for gene expression analysis, and biomarker and target discovery, and our vast and fast-growing gene expression database. We also provide integrated programs ranging from single experiment analyses to multi-milestone efforts that include computational biologists, and use of all of our platforms, AI models and data assets.

Panorama Medicine is a VC-backed startup founded by a multidisciplinary team of world-renowned computational and experimental RNA biologists. Panorama has created PAN, a drug discovery platform that integrates genomics, big data, and computing to develop therapeutic interventions for RNA defects in disease. Research by Panorama and other companies has demonstrated that aberrant RNA splicing underlies a significant number of human diseases. Building industry leading algorithms and vast amount of public and proprietary datasets, Panorama has built the PAN platform to predict splicing events as well as design and screen modalities to address the underlying causes. We look forward to collaboration with the global drug development community to advance medicine and contribute to human knowledge of biology.

Proscia is a software company accelerating pathology's transformation toward a data-driven discipline. Our Concentriq® digital pathology platform and AI-powered computational pathology software are redefining the pathology laboratory and enhancing cancer diagnosis.

Qrono Inc is working on new immunotherapies using our Eloquent platform to target antigen presenting cells and macrophages. Sign up on our website for updates.

QuantumBio is a software and services company that offers a powerful suite of products built on cutting-edge science to provide innovative technical solutions to the life sciences with high accuracy and performance.

Imagine a world where genetic diseases are treated with orally-available small molecule drugs. That's the future Sharp Edge Labs is building. Sharp Edge is a preclinical-stage life sciences company developing drugs for genetic diseases. Our monogenic disease focus de-risks the clinical path. Each pipeline program has a genetically identifiable subset of patients and an early Phase IB pharmacodynamic readout. We combine three core techologies to create a scalable platform for discovery and development. CoreX(tm) is s suite of assay technologies that enable the creation of realistic cellular models of genetic diseases. AlloChem(tm) is a proprietary compound library computationally biased to contain molecules that can bind proteins allosterically, stabilizing them, and restoring their function. Disco/Mine(tm) is a suite of computational and machine learning tools that enhances our experimental approach rather than replacing it. These combine to create a scalable platform with over 10 programs at various stages of development. The company has programs in Frontotemporal Dementia, and genetic subsets of Alzheimer’s and Parkinson’s, as well as lysosomal storage disorders and other loss-of-function diseases. The team and its advisors includes ex and current Genzyme/Sanofi, Synageva, Pfizer and Shire executives.

SoftGenetics, LLC is a biotechnology company based out of 100 Oakwood Avenue Suite 350, State College, Pennsylvania, United States.

We believe that fingerprinting the immune system can be a game-changer when it comes to improving the surgical journey for millions of patients. Combining innovative technologies with artificial intelligence, our multidisciplinary team of clinicians, engineers and scientists is focused on holistically improving the standard-of-care. Predicting the risk for complications before surgery is critical to allow personalization of pre-operative clinical interventions, surgical decision-making and improvement of surgical outcomes. 30% of major surgeries result in complications within 30 days postoperatively, such as infection or pneumonia, and even death. Surge is grounded in more than seven years of clinical, basic science, and translational research led by our team at Stanford University. Our test combines single-cell assessment of the immune system before surgery with clinical data available through Electronic Health Records (EHR) using a proprietary machine learning algorithm. Individual immune systems are comprehensively assessed from a single blood sample obtained before surgery and analyzed using mass cytometry. Our method allows us to mimic surgical trauma in a test tube with a small amount of blood containing millions of immune cells before surgery. We use this technique to understand exactly how every immune cell in your body is responding to the trauma to precisely predict postoperative outcomes.

ThirdLaw Molecular LLC has pioneered the development of Spiroligomer™ molecules and is developing this innovative, patent-protected, therapeutic modality into a new class of more targeted medicines. The mission of the Company is to create a revolutionary category of molecules that transform how diseases are diagnosed and treated – more safely and effectively.